Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

Researchers found that the study cohort had a significantly lower risk for suicidal ideation or attempts during 12 months of follow-up.

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...

A focused review titled "Muscle Mass and Glucagon-like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?" was recently published in the renowned cardiovascular scientific ...

Biologists at Brown University have discovered how a neuropeptide hormone made in the gut of flies can control their lifespan ...

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.

USA: A recent narrative review has highlighted the effectiveness of GLP-1 receptor agonists (RAs) in treating type 2 diabetes ...

Experts reevaluate coverage policies and the financial impact of antiobesity medications based on updated clinical data and ...

Semaglutide use was associated with a lower risk for opioid overdose than other antidiabetic medications in comorbid type 2 diabetes and OUD.